AtriCure Announces 510(k) Clearance for the cryoFORM™ Cryoablation Probe

by BusinessWire

MASON, Ohio--()--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.

“We are excited to bring this new technology to the U.S. market,” said Mike Carrel, President and CEO of AtriCure. “Since the launch in Europe, we have received very positive feedback from our customers, and are looking forward to continued growth in our cryoablation platform.”

The cryoFORM probe builds off of the company’s core strengths in cryoablation technology, leveraging such important features as thermal capacity to remove heat and active defrost, which offers the increased probe flexibility necessary for minimally invasive cardiac surgeries. Building upon those strengths, the new probe offers increased flexibility, allowing the surgeon to more easily manipulate and apply the device and conform to challenging anatomies.

See the full article here.

Save time with kBLASTER's unique result management features of sorting, My Favorites, Saved Search and Search History to quickly find your primary predicate, multiple predicates or reference devices to build a successful 510(k) clearance strategy. Save money by enabling self-service extraction of actionable insight from more than 63,000 FDA medical device 510(k) clearance summaries, plus more than 76,000 splash pages for a total of nearly 140,000 records.